Cor Vasa 2020, 62(1):50-55 | DOI: 10.33678/cor.2019.087

(Athlete's heart vs hypertrophic cardiomyopathy - differential diagnostics according to current guidelines)

Martin Bláha
Klinika kardiologie, Institut klinické a experimentální medicíny, Praha

Hypertrophic cardiomyopathy (HCM) is one of the most common causes of sudden death of young athletes under 35 years of age. Its phenotypic manifestation may resemble the physiological response of the myocardium to a high training load in case of so-called athlete's heart. These two modalities must be distinguished from each other in order to preserve the life of athletes with yet unrecognized HCM, and also on the other side, to avoid unnecessary stopping the career of the healthy ones.

Keywords: Athlete's heart, Cardiac magnetic resonance, ECG, Echocardiography, Genetic testing, Hypertrophic cardiomyopathy

Received: October 18, 2019; Revised: December 2, 2019; Accepted: December 5, 2019; Published: February 28, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bláha M. (Athlete's heart vs hypertrophic cardiomyopathy - differential diagnostics according to current guidelines). Cor Vasa. 2020;62(1):50-55. doi: 10.33678/cor.2019.087.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Maron BJ, Epstein SE, Roberts, WC. Causes of sudden death in competitive athletes. J Am Coll Cardiol 1986;1:204-214. Go to original source... Go to PubMed...
    2. Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 2009;199:1085-1092. Go to original source... Go to PubMed...
    3. Maron BJ, Thompson PD, Ackerman MJ, et al. Recommendations and Considerations Related to Preparticipation Screening for Cardiovascular Abnormalities inCompetitive Athletes: 2007 Update. Circulation 2007;115:1643-1655. Go to original source... Go to PubMed...
    4. Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J 2014;35:2733-2779. Go to original source... Go to PubMed...
    5. Pelliccia A, Solberg EE, Papadakis M, et al. Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies,myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). Eur Heart J 2019;40:19-33 Go to original source... Go to PubMed...
    6. Pagourelias ED, Kouidi E, Vassilikos VP. Recommendations for participation in competitive sport in athletes with hypertrophic cardiomyopathy: opening the sacks of Aeolus. Eur Heart J 2019;40:3064. Go to original source... Go to PubMed...
    7. Weiner RB, Baggish AL. Exercise-induced cardiac remodeling. Prog Cardiovasc Dis 2012;54:380-386. Go to original source... Go to PubMed...
    8. Khan AA, Safi L, Wood M. Cardiac Imaging In Athletes. Methodist Debakey Cardiovasc J 2016;12:86-92. Go to original source... Go to PubMed...
    9. Fisman EZ, Frank AG, Ben-Ari E, et al. Altered left ventricular volume and ejection fraction responses to supine dynamic exercise in athletes. J Am Coll Cardiol 1990;15:582-588. Go to original source... Go to PubMed...
    10. Serra-Grima R, Puig T, Doñate M, et al. Long-term follow-up of bradycardia in elite athletes. Int J Sports Med 2008;29:934-937. Go to original source... Go to PubMed...
    11. Ibarrola M. Ventricular extrasystoles in athletes: what can be learned from the clinical history, clinical examination, the electrocardiogram and the initial approach? e-Journal of Cardiology Practice 2019;14.
    12. Sharma S, Drezner JA, Baggish A, et al. International recommendations for electrocardiographic interpretation in athletes. Eur Heart J 2018;16:1466-1480. Go to original source... Go to PubMed...
    13. Panhuyzen-Goedkoop NM, Jørstad HT, Smeets JLRM. A new consensus document on electrocardiographic interpretation in athletes: does it help to prevent sudden cardiac death in athletes? Neth Heart J 2018;26:127-132. Go to original source... Go to PubMed...
    14. Hernández-Madrid A, Moro C, Marín Huerta E, et al. Third--degree atrioventricular block in an athlete. J Intern Med 1991;229:375-376. Go to original source... Go to PubMed...
    15. Senturk T, Xu H, Puppala K, et al. Cardiac pauses in competitive athletes: a systematic review examining the basis of current practice recommendations. Europace 2016;18:1873-1879. Go to original source... Go to PubMed...
    16. Maron BJ, Udelson JE, Bonow RO, et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis: A Scientific Statement From the American Heart Association and American College of Cardiology. Circulation 2015;132:e273-e280. Go to original source... Go to PubMed...
    17. Hildick-Smith DJR, Shapiro LM. Echocardiographic differentiation of pathological and physiological left ventricular hypertrophy. Heart 2001;85:615-619. Go to original source... Go to PubMed...
    18. Linhart A. Praktický přístup k odlišení atletického srdce od hypertrofické kardiomyopatie. Kardiol Rev Int Med 2007;9:18-23.
    19. Nagashima J, Musha H, Takada H, et al. New upper limit of physiologic cardiac hypertrophy in Japanese participants in the 100 km ultramarathon. J Am Coll Cardiol 2003;42:1617-1623. Go to original source... Go to PubMed...
    20. Malhotra A, Sharma S. Hypertrophic Cardiomyopathy in Athletes. Eur Cardiol 2017;12:80-82. Go to original source... Go to PubMed...
    21. de Almeida Gripp E, Escudini de Oliveira G, Feijó LA, et al. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment. Arq Bras Cardiol 2018;110:140-150. Go to PubMed...
    22. Nardozza M, Chiodi E, Mele D. Left Ventricle Relative Apical Sparing in Cardiac Amyloidosis. J Cardiovasc Echogr 2017;27:141-142. Go to original source... Go to PubMed...
    23. Forsythe L, George K, Oxborough D. Speckle Tracking Echocardiography for the Assessment of the Athlete's Heart: Is It Ready for Daily Practice? Curr Treat Options Cardiovasc Med 2018;20:83. Go to original source... Go to PubMed...
    24. Tsioufis C. "Hearts that strain": Distinguishing athlete's heart from hypertensive disease in the echo lab and beyond. Hell J Cardiology 2018;3:189-191. Go to original source... Go to PubMed...
    25. Pelliccia A, Maron BJ, De Luca R, et al. Remodeling of left ventricular hypertrophy in elite athletes after long-term deconditioning. Circulation 2002;105:944-949. Go to original source... Go to PubMed...
    26. Kramer CM, Neubauer S. Further Refining Risk in Hypertrophic Cardiomyopathy With Late Gadolinium Enhancement by CMR. J Am Coll Cardiol 2018;72:871-873. Go to original source... Go to PubMed...
    27. Mentias A, Raeisi-Giglou P, Smedira NG, et al. Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function. J Am Coll Cardiol 2018;72:857-870. Go to original source... Go to PubMed...
    28. Swoboda PP, Garg P, Levelt E, et al. Regression of Left Ventricular Mass in Athletes Undergoing Complete Detraining Is Mediated by Decrease in Intracellular but Not Extracellular Compartments. Circ Cardiovasc Imaging 2019;12:e009417. Go to original source... Go to PubMed...
    29. Sharma S, Elliott PM, Whyte GW, et al. Utility of metabolic exercise testing in distinguishing hypertrophic cardiomyopathy from physiologic left ventricular hypertrophy in athletes. J Am Coll Cardiol 2000;36:864-870. Go to original source... Go to PubMed...
    30. Rajtar-Salwa R, Hładij R, Petkow Dimitrow P. Elevated Level of Troponin but Not N-Terminal Probrain Natriuretic Peptide Is Associated with Increased Risk of Sudden Cardiac Death in Hypertrophic Cardiomyopathy Calculated According to the ESC Guidelines 2014. Dis Markers 2017;2017:9417908. Go to original source... Go to PubMed...
    31. Leers MP, Schepers R, Baumgarten R. Effects of a long-distance run on cardiac markers in healthy athletes. Clin Chem Lab Med 2006;44:999-1003. Go to original source... Go to PubMed...
    32. Le Goff C, Lennartz L, Vranken L, et al. Comparison of cardiac biomarker dynamics in marathon, semimarathon and untrained runners: what is the impact on results interpretation? J Lab Precis Med 2019;4:6. Go to original source...
    33. Scharhag J, Herrman M, Urhausen A, et al. Independent elevations of N-terminal pro-brain natriuretic peptide and cardiac troponins in endurance athletes after prolonged strenuous exercise. Am Heart J 2005;150:1128-1134. Go to original source... Go to PubMed...
    34. Sheikh N, Papadakis M, Wilson M, et al. Diagnostic Yield of Genetic Testing in Young Athletes With T-Wave Inversion. Circulation 2018;138:1184-1194. Go to original source... Go to PubMed...
    35. Maron BJ, Maron MS, Semsarian C. Genetics of Hypertrophic Cardiomyopathy After 20 Years: Clinical Perspectives. J Am Coll Cardiol 2012;8:705-715. Go to original source... Go to PubMed...
    36. Corrado D, Pelliccia A, Bjørnstad HH, et al. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005;26:516-524. Go to original source... Go to PubMed...
    37. Piro M, Fioranelli, M. Hypertrophic cardiomyopathy screening program in the athlete - second in series. e-Journal of Cardiology Practice 2015;17.
    38. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016;37:2129-2200. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes